Show simple item record

dc.contributor.advisorSantana, Dianaspa
dc.contributor.authorTorres, Jarol
dc.contributor.authorMerchan, Abel
dc.contributor.authorDuque, Angelica
dc.contributor.authorSantana, Diana
dc.coverage.spatialMedicinaspa
dc.date.accessioned2020-03-17T17:26:24Z
dc.date.available2020-03-17T17:26:24Z
dc.date.issued2018-07-12
dc.identifier.urihttp://hdl.handle.net/10654/35120
dc.description.abstractProblema: El reto principal en el manejo de los pacientes con carcinoma de ovario es poder identificar de forma oportuna aquellas pacientes que podrán ser llevados a citorreducción primaria con el objetivo de lograr resección completa del tumor o aquellas que por el contrario se benefician de iniciar manejo neo adyuvante con miras a la realización posterior de cirugía de intervalo. Lo anterior, justificado en el concepto de que la citorreducción primaria es el factor pronóstico más importante en los pacientes con este diagnóstico. En la práctica clínica actual en el Instituto Nacional de Cancerología el reconocimiento de las pacientes candidatas a cirugía de citorreducción primaria se ha realizado a partir de la interpretación de estudios de imagen diagnóstica con un valor predictivo negativo (VPN) del 73%, lo que en muchos casos resulta en la realización de procedimientos quirúrgicos de complejidad significativa con importante morbilidad asociada sin poderse lograr el objetivo inicial propuesto de citorreducción completa de la enfermedad. Lo anterior, plantea la necesidad de buscar otras estrategias diagnósticas que permitan identificar con mayor rendimiento a este grupo de pacientes Objetivo general: Medir el grado de seguimiento y el impacto clínico asociado al uso rutinario del índice de resecabilidad laparoscópico en pacientes con carcinoma epitelial avanzado de ovario, primario peritoneal y de trompas de Falopio (estadios III – IVA) en el Instituto Nacional de Cancerología. Materiales y métodos: Estudio observacional, descriptivo de tipo cohorte prospectiva que incluye a las pacientes con sospecha de carcinoma epitelial de ovario, primario peritoneal o de trompas de Falopio en estadios avanzados (estadios III – IV A), detectado por hallazgos clínicos, imagenológicos y serológicos, que serán atendidas en el Instituto Nacional de Cancerología a partir del año 2017, que en pos de los acuerdos institucionales de la clínica de ginecología oncológica serán llevadas a la medición del índice de resecabilidad laparoscópica. Los registros de historia clínica de estas pacientes serán revisados a los 30 días, a los 6 meses y al año de su valoración clínica inicial, con estos datos se pretende explorar posibles barreras en el seguimiento tanto para la estadificación como para el tratamiento adecuado y oportuno para lo cual se realizará un análisis bivariado exploratorio mediante la prueba exacta de Fisher, usando como variables de desenlace el diagnóstico adecuado, el diagnóstico oportuno, el tratamiento oportuno y el tratamiento adecuado. Para cada covariable explorada se estimarán riesgos relativos e intervalos de confianza del95%. Impacto clínico: Mediante el análisis descriptivo propuesto se identificarán las principales barreras institucionales en el seguimiento oportuno de la medición del índice de resecabilidad laparoscópico y en los casos de diagnóstico y tratamiento oportuno se identificaran beneficios derivados de su utilización tanto en la oportunidad de la atención como en términos de supervivencia libre de enfermedad en la población de estudio.spa
dc.description.sponsorshipInstituto Nacional de Cancerologiaspa
dc.formatpdfspa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.language.isospaspa
dc.publisherUniversidad Militar Nueva Granadaspa
dc.rightsDerechos Reservados - Universidad Militar Nueva Granada, 2020spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.5/co/spa
dc.titleMedición del grado de seguimiento y del impacto clínico asociado al uso rutinario del índice de resecabilidad laparoscópico en pacientes con carcinoma epitelial avanzado de ovario,primario peritoneal y de trompas de Falopio (estadios III – IVA) en el Instituto Nacional de Cancerología.spa
dc.typeinfo:eu-repo/semantics/bachelorThesisspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.publisher.departmentFacultad de Medicinaspa
dc.type.localTrabajo de gradospa
dc.description.abstractenglishProblem: The main challenge in the management of patients with ovarian carcinoma is to be able to identify in a timely manner those patients that may be taken to primary cytoreduction with the aim of achieving complete resection of the tumor or those that on the contrary benefit from starting management neo adjuvant with a view to the subsequent performance of interval surgery. The above, justified in the concept that primary cytoreduction is the most important prognostic factor in patients with this diagnosis. In the current clinical practice at the National Cancer Institute, the recognition of patients who are candidates for primary cytoreduction surgery has been carried out based on the interpretation of diagnostic imaging studies with a negative predictive value (NPV) of 73%, which in many cases result in performing surgical procedures of significant complexity with significant associated morbidity without being able to achieve the proposed initial goal of complete cytoreduction of the disease. The foregoing raises the need to look for other diagnostic strategies that allow this group of patients to be identified with greater performance. General objective: To measure the degree of follow-up and the clinical impact associated with the routine use of the laparoscopic resectability index in patients with advanced epithelial carcinoma of ovary, primary peritoneal and fallopian tubes (stages III - VAT) at the National Cancer Institute. Materials and methods: An observational, descriptive, prospective cohort study that includes patients with suspected epithelial carcinoma of the ovary, peritoneal primary or fallopian tubes in advanced stages (stages III - IV A), detected by clinical, imaging and clinical findings. serological, which will be treated at the National Cancer Institute from 2017, which after the institutional agreements of the oncological gynecology clinic will be taken to measure the laparoscopic resectability index. The records of the medical history of these patients will be reviewed at 30 days, at 6 months and one year after their initial clinical evaluation, with these data it is intended to explore possible barriers to follow-up both for staging and for adequate and timely treatment. for which an exploratory bivariate analysis will be carried out using Fisher's exact test, using the appropriate diagnosis, the appropriate diagnosis, the appropriate treatment and the appropriate treatment as the outcome variables. For each covariate explored, relative risks and 95% confidence intervals will be estimated. Clinical impact: Through the proposed descriptive analysis, the main institutional barriers will be identified in the timely follow-up of the measurement of the laparoscopic resectability index and in cases of diagnosis and timely treatment, benefits derived from its use will be identified both in the opportunity of care and in terms of disease-free survival in the study population.eng
dc.title.translatedMeasurement of the degree of follow-up and clinical impact associated with the routine use of the laparoscopic resectability index in patients with advanced epithelial carcinoma of the ovary, primary peritoneal and fallopian tubes (stages III - VIA) at the National Cancer Institute.spa
dc.subject.keywordsOvaryspa
dc.subject.keywordsFagotti indexspa
dc.subject.keywordsCancerspa
dc.publisher.programGinecología Oncológicaspa
dc.creator.degreenameEspecialista en Ginecología Oncológicaspa
dc.subject.decsNEOPLASMAS EMBRIONARIOS
dc.subject.decsGINECOLOGIA
dc.subject.decsLAPAROSCOPIA
dc.subject.decsENFERMEDADES DEL APARATO GENITAL FEMENINO
dc.contributor.corporatenameSuescun, Oscarspa
dc.contributor.corporatenameCalderon, Pedrospa
dc.contributor.corporatenameMedina, Monicaspa
dc.contributor.corporatenameTrujillo, Linaspa
dc.contributor.corporatenameAcosta, Jesusspa
dc.contributor.corporatenameVallejo, Mariaspa
dc.description.degreelevelEspecializaciónspa
dc.publisher.facultyMedicina y Ciencias de la Salud - Ginecología Oncológicaspa
dc.type.dcmi-type-vocabularyTextspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadasspa
dc.relation.referencesNCCN Clinical Practice Guidelines in Oncology. Ovarian cáncer including fallopian tuve cáncer and primary peritoneal cáncer Version2.2016spa
dc.relation.referencesFerlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on day/month/year.spa
dc.relation.referencesGeurts SM, de Vegt F. Considering early detection of relapsed ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2011 Jul;21(5):837-45spa
dc.relation.referencesChang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol2013;130:493–8.spa
dc.relation.referencesSchorge J, Clark Rachel, Lee Susanna, Penson Richard. Primary debulking surgery for advance ovarian cáncer: Are you a believer or a dissenter? Gynecologic Oncology 135 (2014) 595–605.spa
dc.relation.referencesRodríguez Gómez Natalia, Martínez Bertha Alejandra, Alpa Nick. Predictors of optimal cytoreduction in patinets with newly diagnosed advanced – stage epitelial ovarian cáncer: Time to incorpórate laparoscopic assessment into the standard of care. Gynecologic Oncology 137 (2015)553–558.spa
dc.relation.referencesVergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431–6.spa
dc.relation.referencesFagotti A, Fanfani F, Ludovisi M, Lo Voi R, Bifulco G, Testa AC, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol 2005;96:729–35.spa
dc.relation.referencesFagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A laparoscopy based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006;13:1156–61.spa
dc.relation.referencesFagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli F, Carone V, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol 2008;199:642.e1–6.spa
dc.relation.referencesFagotti A, Vizzielli G, De Iaco P, Surico D, Buda A, Mandato VD, et al. A multicentric trial (Olympia- MITO13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol 2013;209 (462.e1-11).spa
dc.relation.referencesFagotti A, Fanfani F, Vizzielli G, Gallota V, Ercoli A, Paglia A, et al. Should laparoscopy be included in the work up of advanced ovarian cancer patients attempting interval debulking surgery? Gynecol Oncol 2010;116:72–7.spa
dc.relation.referencesFagotti A, Vizzielli G, Fanfani F, Costantini B, Ferrandina G, Gallotta V, et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol Oncol 2013;131:341– 346.spa
dc.relation.referencesPaul H. Sugarbaker. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer . Current Opinion in Obstetrics and Gynecology 2009, 21:15–24.spa
dc.relation.referencesPetrillo M, Vizzielli G, Fanfani F, et al. Definition of adynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. Gynecol Oncol. 2015.spa
dc.relation.referencesPardo C, Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Primera edición. Bogotá. D.C. Instituto Nacional de Cancerología, 2015, v.1. p. 123spa
dc.relation.referencesAlpa m. nick, robert l. coleman, pedro t. ramirez and anil k. sood. A framework for a personalized surgical approach to ovarian cáncer. Nat. Rev. Clin. Oncol 2015. 12, 239–245.spa
dc.relation.referencesGlobocan. Cervix uteri - Estimated mortality, all ages [Internet]. [cited 2015 Mar 8]. Availablefrom:spa
dc.subject.proposalOvariospa
dc.subject.proposalIndice fagottispa
dc.subject.proposalCancerspa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Derechos Reservados - Universidad Militar Nueva Granada, 2020
Except where otherwise noted, this item's license is described as Derechos Reservados - Universidad Militar Nueva Granada, 2020